About Hospital-acquired Diseases
Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient.
Technavio's analysts forecast the global hospital-acquired disease testing market to grow at a CAGR of 19.44% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and the growth prospects of the global hospital-acquired disease testing market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of testing products used in the following hospital-acquired disease infections: SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and others.
Technavio's report, Global Hospital-acquired Disease Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital-acquired disease testing market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Abbott Laboratories
• Becton and Dickenson
• bioMerieux
• Roche Diagnostics
Other Prominent Vendor
• Akers Biosciences
• Alere
• Beckman Coulter/Danaher
• Cantel Medical
• Cepheid
• Diatherix Laboratories
• Eiken Chemical
• Enzo Biochem
• Fujirebio/Innogenetics
• Gen-Probe
• Humor Diagnostica
• Life Technologies
• Meridian Bioscience
• Nordion
• QIAGEN
Market Driver
• Rising Prevalence of HAIs
• For a full, detailed list, view our report
Market Challenge
• Lack of Healthcare Infrastructure
• For a full, detailed list, view our report
Market Trend
• Technological Advancements
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Hospital Acquired Infections/Hospital Acquired Diseases
07.1 Background
07.1.1 Symptoms, Prevention, Testing, and Diagnosis of HAIs
07.2 Incidence and Prevalence of HAI
07.2.1 Developed Nations
07.2.2 Low and Middle-income Nations
08. Market Segmentation by Product
08.1 Global UTI Testing Market
08.1.1 Market Size and Forecast
08.2 Global SSI Testing Market
08.2.1 Market Size and Forecast
08.3 Global Pneumococcal Infections Testing Market
08.3.1 Market Size and Forecast
08.4 Global Bloodstream Infections Testing Market
08.4.1 Market Size and Forecast
08.5 Global MRSA Testing Market
08.5.1 Market Size and Forecast
09. Geographical Segmentation
09.1 Hospital Acquired Disease Testing Market in Americas
09.1.1 Market Size and Forecast
09.2 Hospital Acquired Disease Testing Market in EMEA
09.2.1 Market Size and Forecast
09.3 Hospital Acquired Disease Testing Market in APAC
09.3.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Abbott
17.2.2 BD
17.2.3 bioMerieux
17.2.4 Roche Diagnostics
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Abbott Laboratories
18.1.1 Key Facts
18.1.2 Business Description
18.1.3 Business Segmentation
18.1.4 Business Strategy
18.1.5 Revenue by Business Segmentation
18.1.6 Revenue Comparison 2011 and 2012
18.1.7 Revenue by Geographical Segmentation
18.1.8 Key Information
18.1.9 SWOT Analysis
18.2 Becton, Dickinson and Co.
18.2.1 Key Facts
18.2.2 Business Description
18.2.3 Business Segmentation
18.2.4 Revenue Segmentation by Business
18.2.5 Segmental Revenue Comparison 2013 and 2012
18.2.6 Revenue Segmentation by Geography
18.2.7 Business Strategy
18.2.8 Key Developments
18.2.9 SWOT Analysis
18.3 bioMeriux
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2013
18.3.4 Geographical Segmentation by Revenue 2013
18.3.5 Business Strategy
18.3.6 Recent Developments
18.3.7 SWOT Analysis
18.4 Roche Diagnostics
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2014
18.4.4 Business Segmentation by Revenue 2013 and 2014
18.4.5 Geographical Segmentation by Revenue 2014
18.4.6 Business Strategy
18.4.7 Recent Developments
18.4.8 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Hospital Acquired Disease Testing Market 2014-2019 ($ millions)
Exhibit 3: Common HAIs in Acute Care Settings
Exhibit 4: Prevalence of HAI in Developed Nations
Exhibit 5: Prevalence of HAI in Low and Middle-Income Nations
Exhibit 6: Comparison of HAI in Developed and Low and Middle-income Nations
Exhibit 7: Hospital Acquired Infections in US (2011)
Exhibit 8: Estimated Treatment Cost and Mortality Associated with HAIs
Exhibit 9: Segmentation of Global Hospital Acquired Disease Testing Market by Product 2014
Exhibit 10: Global UTI Testing Market 2014-2019 ($ millions)
Exhibit 11: Global SSI Testing Market 2014-2019 ($ millions)
Exhibit 12: Global Pneumococcal Infections Testing Market 2014-2019 ($ millions)
Exhibit 13: Global Bloodstream Infections Testing Market 2014-2019 ($ millions)
Exhibit 14: Global MRSA Testing Market 2014-2019 ($ millions)
Exhibit 15: Global Hospital Acquired Disease Testing Market Segmentation Analysis 2014-2019
Exhibit 16: Segmentation of Global Hospital Acquired Disease Testing Market by Product Type 2014-2019
Exhibit 17: Global Hospital Acquired Disease Testing Market by Geographical Segmentation 2014
Exhibit 18: Hospital Acquired Disease Testing Market in Americas 2014-2019 ($ millions)
Exhibit 19: Hospital Acquired Disease Testing Market in EMEA 2014-2019 ($ millions)
Exhibit 20: Hospital Acquired Disease Testing Market in APAC 2014-2019 ($ millions)
Exhibit 21: Global Hospital Acquired Disease Testing Market Segmentation by Geography 2014-2019 ($ millions)
Exhibit 22: Global Hospital Acquired Disease Testing Market Segmentation by Geography (%)
Exhibit 23: Percentage of Elderly Aged above 65 in Different Regions 2012 and 2050
Exhibit 24: Estimated Percentage of Elderly Population 2012 and 2050
Exhibit 25: Immediate Control Measures for Management of HAIs
Exhibit 26: Direct Costs and Prevalence of HAI in Europe and US
Exhibit 27: Abbott Laboratories: Key Takeaways
Exhibit 28: BD: Key Takeaways
Exhibit 29: bioMerieux: Key Takeaways
Exhibit 30: Roche Diagnostics: Key Takeaways
Exhibit 31: Abbott Laboratories: Business Segmentation
Exhibit 32: Abbott Laboratories: Revenue by Business Segmentation 2012
Exhibit 33: Abbott Laboratories: Revenue by Business Segmentation 2011 and 2012 ($ millions)
Exhibit 34: Abbott Laboratories: Revenue by Geographical Segmentation 2012
Exhibit 35: Becton, Dickinson and Co.: Product Categorization
Exhibit 36: Becton, Dickinson and Co.: Revenue Segmentation 2013
Exhibit 37: Becton, Dickinson and Co.: Revenue Comparison ($ millions)
Exhibit 38: Becton, Dickinson and Co.: Geographical Segmentation 2013
Exhibit 39: bioMeriux: Business Segmentation by Revenue 2013
Exhibit 40: bioMeriux: Geographical Segmentation by Revenue 2013
Exhibit 41: Roche Diagnostics: Business Segmentation by Revenue 2014
Exhibit 42: Roche Diagnostics: Business Segmentation by Revenue 2013 and 2014 ($ billion)
Exhibit 43: Roche Diagnostics: Geographical Segmentation by Revenue 2014
